Managed Care Pharmacy Tools

Disparities in Medication Use and Access

Policy 2101

02/22/2022 Introduced

AMCP stands against racial and health care injustice. AMCP acknowledges that health care disparities occur across a multitude of factors, including race, ethnicity, and socioeconomics. To increase health care access for all, it is imperative to collect, evaluate, and incorporate data on race, ethnicity, and socioeconomic factors and evaluate the association of these factors on medication use and access. In addition, these factors should be considered when implementing interventions, developing benefit offerings, and designing formularies.

AMCP supports the development and training of managed care pharmacists and other health care professionals, students, and educators in diversity and inclusion practices to ensure that equitable access to quality care is available to all patients, both in clinical programs and overall care.

Drug Use Management

Policy 9909

11/01/1999 Introduced
03/01/2004 Reapproved
12/01/2008 Reapproved
10/01/2012 Reapproved

02/08/2017 Reapproved

AMCP recognizes the value of drug use review (DUR) as a means to understand, interpret, evaluate, and improve the prescribing, administration, and use of medications to improve patient outcomes and total cost of care. Using DUR information, managed care pharmacists can identify prescribing trends and initiate corrective action in collaboration with appropriate stakeholders to improve drug therapy for groups of patients, as well as individuals.

(See AMCP Concepts in Managed Care Pharmacy – Drug Use Evaluation)

Therapeutic Interchange

Policy 9928

11/01/1999 Introduced
03/01/2004 Reapproved
12/01/2008 Reapproved
10/01/2012 Revised
03/25/2019 Revised
02/08/2024 Revised

03/25/2019 Revised

AMCP supports the use of evidence-based therapeutic interchange programs as a part of a comprehensive approach to quality, cost-effective patient care. AMCP believes that therapeutic interchange may improve the patient's access to more affordable health care and represents an efficient use of pharmaceutical resources that helps keep medical costs down. The therapeutic interchange programs are designed to work in conjunction with other tools that health care professionals use to promote quality medical outcomes, and increase affordability to patients and payers. Therapeutic interchange is not always about simply lowering the medication costs; however, therapeutic interchange frequently occurs when overall health care savings can be achieved. There are instances where replacing one drug with a more costly drug may result in fewer treatment failures, better patient adherence to the treatment plan, fewer side effects, and improved clinical outcomes, which could result in lower overall health care spending.

(See AMCP Managed Care Pharmacy Practice Positions - Therapeutic Interchange)

Development of Quality Performance Measures

Policy 0006

02/01/2000 Introduced
02/01/2005 Revised
11/01/2009 Revised
02/21/2018 Revised
02/08/2023 Revised  

Patient Adherence and Persistence

Policy 0115

11/01/2001 Introduced
02/01/2006 Revised
12/01/2010 Revised

04/07/2015 Revised

Medicare Quality Measures

Policy 1403

10/07/2014 Introduced

10/28/2022 Revised

AMCP recognizes the essential role of pharmacists, PBMs, and health plans in improving the quality of care provided to patients and supports a measure development process that allows for timely integration of evidence-based medicine and feedback from stakeholders. AMCP additionally emphasizes the need to align measures across Medicare benefit programs to promote consistency, economic efficiency, and quality across the health care system. Quality measure policies need to be evaluated to ensure fair competition across all Medicare plan sponsors. 

(See AMCP Future of Medicare Part D Statement – Medicare Part D Quality Measures)